Teva Reports FDA Approval for Degevma

MT newswire2026/09/28 20:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:25 PM EDT, 09/28/2026 (MT Newswires) -- Teva Pharmaceutical Industries (TEVA) said late Monday the US Food and Drug Administration has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, it said. The drug is also indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy, Teva said. Teva said it expects to launch Degevma and Ponlimsi in the US in the coming months. Ponlimsi was approved in March.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Locked for new tokens.

APR up to 10%. Always on, always get airdrop.

Lock now!

Japan Post Insurance announced plans to increase its purchases of yen-denominated bonds, while Daido Life Insurance has raised its target for domestic bond holdings, focusing mainly on corporate bonds. Meiji Yasuda Life Insurance plans to keep its holdings of Japanese government bonds largely unchanged but will swap low-yield bonds for higher-yield varieties. This week, the 20-year government bond auction recorded a historic high bid-to-cover ratio, and life insurance institutions have been net buyers of super-long-term Japanese government bonds for four consecutive months.

华尔街见闻•2026/10/21 19:21